查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1937737

2026-2034年全球甲癬治療市場規模、佔有率、趨勢和成長分析報告

Global Onychomycosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計甲癬治療市場將從 2025 年的 57.8 億美元成長到 2034 年的 125.1 億美元，2026 年至 2034 年的複合年成長率為 8.97%。

受真菌性甲癬感染疾病率上升和人們對現有治療方案認知度提高的推動，甲癬治療市場預計將迎來顯著成長。甲癬的特徵是甲床及周圍組織感染，影響相當一部分人群，造成不適和美觀問題。隨著醫療服務提供者和患者都認知到有效治療的重要性，對創新治療方法的需求預計將會增加。該市場正朝著更有效、更人性化的治療方法轉變，包括局部抗真菌藥物、口服藥物和雷射療法。

除了傳統治療方法外，灰指甲治療市場也受益於藥物製劑技術和給藥系統的進步。能夠增強抗真菌藥物滲透到甲母質的新型製劑備受關注，從而提高了治療效果並縮短了療程。此外，針對感染多個方面的聯合治療的開發正成為一種很有前景的方法，為患者提供更全面的解決方案。隨著研究的深入和新的治療標靶及作用機制的揭示，甲癬治療市場預計將持續成長，為患者提供更多有效的治療選擇。

此外，對預防保健和病患教育的日益重視正在重塑甲癬的治療模式。醫療服務提供者強調早期診斷和介入的重要性，並致力於教育患者正確的足部衛生和指甲護理方法。隨著患者對未經治療的真菌感染疾病風險有了更深入的了解，這種積極主動的治療方法可能會增加對治療方案的需求。隨著甲癬治療市場的不斷發展，創新的治療方法組合、加強患者教育以及注重預防將在應對這種常見疾病帶來的挑戰方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球甲癬治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 藥物
  • 雷射
  • 動態療法

第5章：全球甲癬治療市場：依適應症分類

  • 市場分析、洞察與預測
  • 遠端甲下甲癬
  • 白色淺層甲癬
  • 近端甲下甲癬
  • 念珠菌性甲癬
  • 全甲癬

第6章：全球甲癬治療市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 0-18歲
  • 18至39歲
  • 40至64歲
  • 65歲或以上

第7章 全球甲癬治療市場：依性別分類

  • 市場分析、洞察與預測
  • 男性
  • 女士

第8章：全球甲癬治療市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 向機構銷售
  • 零售銷售

第9章 全球甲癬治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd
    • Sanofi SA
    • Medimetriks Pharmaceuticals Inc
    • Galderma
    • Johnson & Johnson
    • Novartis AG
    • Moberg Pharma AB
    • Cardinal Health Inc
    • Pfizer Inc
    • Almirall SA
    • Bayer AG
    • Viatris Inc
    • GlaxoSmithKline Plc
    • Cipla Ltd
    • Dr. Reddy'S Laboratories Ltd
簡介目錄
Product Code: VMR11215983

The Onychomycosis Treatment Market size is expected to reach USD 12.51 Billion in 2034 from USD 5.78 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The onychomycosis treatment market is poised for significant growth, driven by the increasing prevalence of fungal nail infections and the rising awareness of available treatment options. Onychomycosis, characterized by the infection of the nail bed and surrounding tissues, affects a substantial portion of the population, leading to discomfort and aesthetic concerns. As healthcare providers and patients alike recognize the importance of effective treatment, the demand for innovative therapies is expected to rise. This market is witnessing a shift towards more effective and patient-friendly treatment modalities, including topical antifungals, oral medications, and laser therapies.

In addition to traditional treatment options, the onychomycosis treatment market is benefiting from advancements in drug formulation and delivery systems. Novel formulations that enhance the penetration of antifungal agents into the nail matrix are gaining traction, improving treatment efficacy and reducing the duration of therapy. Furthermore, the development of combination therapies that target multiple aspects of the infection is emerging as a promising approach, offering patients a more comprehensive solution. As research continues to unveil new therapeutic targets and mechanisms of action, the onychomycosis treatment market is expected to expand, providing patients with a wider array of effective treatment options.

Moreover, the increasing focus on preventive care and patient education is shaping the onychomycosis treatment landscape. Healthcare providers are emphasizing the importance of early diagnosis and intervention, as well as educating patients about proper foot hygiene and nail care practices. This proactive approach is likely to drive demand for treatment options, as patients become more informed about the risks associated with untreated fungal infections. As the onychomycosis treatment market continues to evolve, the combination of innovative therapies, enhanced patient education, and a growing emphasis on prevention will play a crucial role in addressing the challenges posed by this common condition.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Drugs
  • Lasers
  • Photodynamic Therapy

By Disease Indication

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By Age Group

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

By Gender

  • Male
  • Female

By Distribution Channel

  • Institutional Sales
  • Retail Sales

COMPANIES PROFILED

  • Teva Pharmaceutical Industries Ltd, Sanofi SA, Medimetriks Pharmaceuticals Inc, Galderma, Johnson Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health Inc, Pfizer Inc, Almirall SA, Bayer AG, Viatris Inc, GlaxoSmithKline plc, Cipla Ltd, Dr Reddys Laboratories Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lasers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Photodynamic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Indication
  • 5.2. Distal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. White Superficial Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Proximal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Candidal Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Total Dystrophic Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. 0 to 18 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. 18 to 39 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. 40 to 64 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. 65 Years & Above Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Gender
  • 7.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Treatment Type
    • 9.2.2 By Disease Indication
    • 9.2.3 By Age Group
    • 9.2.4 By Gender
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Treatment Type
    • 9.3.2 By Disease Indication
    • 9.3.3 By Age Group
    • 9.3.4 By Gender
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Treatment Type
    • 9.4.2 By Disease Indication
    • 9.4.3 By Age Group
    • 9.4.4 By Gender
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Treatment Type
    • 9.5.2 By Disease Indication
    • 9.5.3 By Age Group
    • 9.5.4 By Gender
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Treatment Type
    • 9.6.2 By Disease Indication
    • 9.6.3 By Age Group
    • 9.6.4 By Gender
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONYCHOMYCOSIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Teva Pharmaceutical Industries Ltd
    • 11.2.2 Sanofi S.A
    • 11.2.3 Medimetriks Pharmaceuticals Inc
    • 11.2.4 Galderma
    • 11.2.5 Johnson & Johnson
    • 11.2.6 Novartis AG
    • 11.2.7 Moberg Pharma AB
    • 11.2.8 Cardinal Health Inc
    • 11.2.9 Pfizer Inc
    • 11.2.10 Almirall S.A
    • 11.2.11 Bayer AG
    • 11.2.12 Viatris Inc
    • 11.2.13 GlaxoSmithKline Plc
    • 11.2.14 Cipla Ltd
    • 11.2.15 Dr. Reddy'S Laboratories Ltd